Please login to the form below

Not currently logged in
Email:
Password:

drug reimbursement

This page shows the latest drug reimbursement news and features for those working in and with pharma, biotech and healthcare.

Orphan drugs market to soar to $224bn by 2024

Orphan drugs market to soar to $224bn by 2024

orphan drug product in 2024, and will help bring in total orphan drug sales of $13.7bn for the company. ... in 2018 versus $33, 654 for a non-orphan drug, explain much of the allure,” says the report.

Latest news

  • Urovant slips on phase 3 incontinence drug data Urovant slips on phase 3 incontinence drug data

    As tolterodine is generically available that has raised questions about whether doctors would be prepared to prescribe vibegron – and moreover if insurers would back reimbursement of the drug – ahead of a ... If approved, it would become the first

  • Drug pricing is pharma’s top concern in 2019 Drug pricing is pharma’s top concern in 2019

    Drug pricing and reimbursement remains at the forefront of pharma executive minds as 2019 gets underway, according to a new industry survey. ... Unphased by the data, Trump told a cabinet meeting this week that “you’re going to see a tremendous

  • Better together when buying medicines? Taking stock of the BeNeLuxA initiative Better together when buying medicines? Taking stock of the BeNeLuxA initiative

    Apply that to the fragmented and diverse landscape of drug pricing and reimbursement in Europe and the reality becomes a lot more complicated. ... There is MEDEV too, an informal cooperation on the assessment, pricing and reimbursement of medicines in

  • Vertex rises on data for cystic fibrosis triple therapy Vertex rises on data for cystic fibrosis triple therapy

    Company will wait for further results before filing. Vertex Pharma has unveiled the first phase 3 data from its highly-anticipated three-drug combination for cystic fibrosis (CF), setting up a ... The interim results come from two studies of its two-drug

  • Health secretary’s ‘rip off’ remarks anger UK pharma Health secretary’s ‘rip off’ remarks anger UK pharma

    Negotiations over the pricing and reimbursement for the drug have been going on for two years, with both sides claiming they have made exceptional offers. ... they need instead to accept the deal and supply the drug right now.”.

More from news
Approximately 36 fully matching, plus 55 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 7 fully matching, plus 19 partially matching documents found.

Latest appointments

  • Extension for head of Germany’s VFA Extension for head of Germany’s VFA

    She has led the industry voice during an unsettled time for pharma in Germany with many companies critical of the AMNOG system of drug reimbursement introduced in 2010, which has seen

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Webinar: Usability and UX: You’ve been asked to test...What next?
Thursday 27th June 2019 10am EDT / 3pm BST / 4pm CEST...
Event: EphMRA Annual Conference
We're sponsoring, exhibiting and presenting three papers at this year’s EphMRA Annual Conference in Warsaw, Poland....
Research Partnership and Janssen awarded runner-up in MR Excellence Awards
...

Infographics